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Abstract
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis
(TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug
resistant TB. Through the use of high throughput whole cell screening of an extensive compound library a number of
imidazo[1,2-a]pyridine (IP) compounds were obtained as potent lead molecules active against M. tuberculosis and
Mycobacterium bovis BCG. The IP inhibitors (1–4) demonstrated minimum inhibitory concentrations (MICs) in the range of
0.03 to 5 mM against a panel of M. tuberculosis strains. M. bovis BCG spontaneous resistant mutants were generated against
IP 1, 3, and 4 at 56 MIC and subsequent whole genome sequencing identified a single nucleotide polymorphism
937ACC.937GCC (T313A) in qcrB, which encodes the b subunit of the electron transport ubiquinol cytochrome C reductase.
This mutation also conferred cross-resistance against IP 1, 3 and 4 demonstrating a common target. Gene dosage
experiments confirmed M. bovis BCG QcrB as the target where over-expression in M. bovis BCG led to an increase in MIC
from 0.5 to .8 mM for IP 3. An acute murine model of TB infection established bacteriostatic activity of the IP series, which
await further detailed characterization.
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Introduction
The Gram-positive bacillus, Mycobacterium tuberculosis, is a major
human pathogen and is the causative agent of tuberculosis (TB).
This infectious disease poses a global health risk with an incidence
rate of 8.8 million cases and a fatality rate of 1.4 million [1,2,3].
Co-infection with Human Immunodeficiency Virus (HIV) aug-
ments the number of TB cases and the development of active
tuberculosis [1,3]. As such, there remains an urgent requirement
for new anti-tubercular drugs [4]. This has been further
compounded by the emergence of drug resistance that has
rendered existing treatment programs ineffective. In 2010, an
estimated 650,000 cases of multi-drug resistant TB (MDR-TB)
were reported [5] and since then, extensively-drug resistant TB
(XDR-TB) and totally-drug resistant TB (TDR-TB) have been
established [6]. Evidently, the development of successful anti-
tubercular agents is imperative, but simultaneously faces a myriad
of challenges. These include: meeting the directives of shortening
treatment duration; dosing frequency; co-administration with HIV
medications; reducing adverse effects [4]. Thus, to circumvent an
era where TB is untreatable, the discovery of unique drug targets
and novel inhibitory compounds can be considered invaluable in
terms of meeting the current and future therapeutic needs to
relieve the burden of TB cases worldwide [4].
Tackling this problem, many researchers in the area of drug
discovery are now shifting from single-enzyme to whole cell
phenotypic approaches, using High Throughput Screening
(HTS) of extensive compound libraries [7,8,9,10]. For example,
the diarylquinoline family of M. tuberculosis inhibitors were
identified utilizing a whole cell phenotypic HTS campaign of a
library of more than 70,000 compounds against Mycobacterium
smegmatis [11,12,13]. The lead compound diarylquinoline
TMC207 was then subsequently identified as a potent inhibitor
of the M. tuberculosis ATP synthase through whole genome
sequencing of spontaneous resistant mutants [11,12]. In addition
to the potency of TMC207 against both drug-sensitive and
MDR-TB strains, the recent success in Phase II clinical trials
places TMC207 as a future front-line anti-tubercular agent [13].
Similarly, the M. tuberculosis inhibitors SQ109 [14,15,16]
adamantly ureas [17,18], and benzimidazole [19] were identi-
fied following HTS campaigns and chemical lead optimization.
The cellular target of SQ109 [20], adamantly ureas [17],
pyrrole BM212 [21], and benzimidazoles [19], has recently
been identified by whole genome sequencing of spontaneous
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resistant mutants generated against each inhibitor series, which
revealed the common target MmpL3, a membrane transporter
involved in the export of trehalose monomycolate (TMM) and
cell wall biosynthesis [17,20,21,22].
Another inhibitor series found to have anti-TB activity are the
imidazo[1,2-a]pyridine-3-nitroso compounds, but they exhibit
undesirable toxicity in a VERO cell line [23]. A similar family
of compounds, the imidazo[1,2-a]pyridine-3-hydrazones, have
been synthesized but are all inactive against M. tuberculosis
H37Rv [24]. More recently, 3-amino-imidazo[1,2-a]pyridines
were shown as M. tuberculosis glutamine synthetase inhibitors
[25]. The anti-TB properties of the 2,7-dimethylimidazo[1,2-
a]pyridine-3-carboxamides have also been investigated [26]. These
compounds are synthetically tractable, possess druggable proper-
ties, and have excellent selective potency against MDR- and
XDR-TB [10,27]. We have performed a HTS campaign, which
has also identified imidazo[1,2-a]pyridines (IP) as potent inhibitors
of M. tuberculosis and M. bovis BCG. Herein we describe four
inhibitors of the IP series (Figure 1, Table 1) and demonstrate that
IP specifically targets QcrB, which encodes the b subunit of the
electron transport ubiquinol cytochrome C reductase.
Materials and Methods
Ethics Statement
All experiments were approved by the Diseases of the
Developing World (DDW-GSK) ethical committee. The animal
research complies with Spanish and European Union legislation
(European directive 86/609/EEC) on animal research and
GlaxoSmithKline 3R policy on the care and use of animals:
Replacement, Reduction and Refinement.
General Information
All commercially available reagents and solvents were used
without further purification. Automated flash chromatography was
performed on a Biotage FlashMaster II system with peak detection
at 254 nm. All products were obtained as amorphous solids and
melting points were not measured. 1H NMR spectra were
recorded at 300 MHz on a Varian spectrometer. Chemical shifts
(d) are given in ppm relative to the solvent reference as an internal
standard (d6-DMSO, d=2.50 ppm). Data are reported as follows:
chemical shift (multiplicity (s for singlet, d for doublet, t for triplet,
m for multiplet, br for broad), integration, coupling constant(s) in
Hz). HPLC–MS analyses were conducted on an Agilent 1100
instrument equipped with a Sunfire C18 column (30 mm x 2.1 mm
i.d., 3.5 mm packing diameter) at 40uC coupled with a Waters
ZMD2000 mass spectrometer; the method of ionization was
alternate-scan positive and negative electrospray. Compounds had
purity of .98%, as determined by HPLC and 1H NMR analysis.
All commercially available compounds, including hit molecules 1
and 2, were used without further purification.
Chemical Synthesis of Compounds 3 and 4
2,6-Dimethyl-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyri-
dine-3-carboxamide (3). To a mixture of 2,6-dimethylimidazo[1,2-
a]pyridine-3-carboxylic acid (2.5 g, 13.14 mmol) and dichloro-
methane (200 ml), N-(3-dimethylaminopropyl)-N9-ethylcarbodii-
mide hydrochloride (3.78 g, 19.72 mmol), 1-hydroxy-1H-benzo-
triazol hydrate (3.02 g, 19.72 mmol) and N,N-
diisopropylethylamine (2.68 ml, 15.77 mmol) were added. After
stirring for 15 minutes at room temperature, (4-(trifluoromethyl)-
phenyl)methanamine (1.873 ml, 13.14 mmol) was added. The
reaction was stirred at room temperature for 4.5 hours and
NaHCO3 (200 ml) was added. The organic layer was washed with
Figure 1. Compounds from the IP series active againstM. tuberculosis. Structures of the initial IP hits (1 and 2) identified in the HTS campaign
against M. bovis BCG (activity later confirmed in M. tuberculosis) and of optimized compounds 3 and 4.
doi:10.1371/journal.pone.0052951.g001
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NaCl (200 ml) and dried over Na2SO4, filtered, and concentrated
under reduced pressure. The crude mixture was purified using a
silica gel cartridge (Analogix) and eluted with a mixture of
methanol/dichloromethane (gradient 0–5%). Collected fractions
were evaporated under reduced pressure to obtain the title
compound 3 (4.0 g, 11.52 mmol, 88% yield) as a white solid. MS
(m/z) = 348 ([M+H]+); 1H NMR: d 8.86 (br s, 1H), 8.37 (br t, 1H,
J=5.8), 7.72 and 7.60 (AA9BB9 system, 4H), 7.49 (d, 1H, J=9.1),
7.26 (dd, 1H, J=9.1 and 1.8), 4.61 (d, 2H, J=6.1), 2.60 (s, 3H),
2.30 (s, 3H).
N-((6-Chloropyridin-3-yl)methyl)-2,6-dimethylimidazo[1,2-
a]pyridine-3-carboxamide (4). To a mixture of (6-chloropyridin-3-
yl)methanamine (94 mg, 0.66 mmol) and dichloromethane
(20 ml), N,N-diisopropylethylamine (0.246 ml, 1.45 mmol) was
added. After stirring for 20 minutes at 0uC, 2,6-dimethylimi-
dazo[1,2-a]pyridine-3-carboxylic acid (125 mg, 0.66 mmol), 1-
hydroxy-1H-benzotriazol hydrate (151 mg, 0.99 mmol), and
DMF (1 ml) were added. The mixture was stirred at 0uC for 1.5
hours and then N-(3-dimethylaminopropyl)-N9-ethylcarbodiimide
hydrochloride (189 mg, 0.99 mmol) was added. The reaction was
stirred at room temperature for 24 hours. The reaction was
quenched and washed with saturated aqueous NaHCO3
(2615 ml), brine (15 ml), and H2O (15 ml), dried over MgSO4,
filtered, and concentrated under reduced pressure. The crude
mixture was purified using a silica gel cartridge (Analogix) and
eluted with a mixture of methanol/dichloromethane (gradient 0–
5%). Collected fractions were evaporated under reduced pressure
to obtain the title compound 4 (104 mg, 0.33 mmol, 50% yield) as
a white solid. MS (m/z) = 315 ([M+H]+); 1H NMR: d 8.87–8.85
(m, 1H), 8.44 (d, 1H, J=2.0) 8.33 (br t, 1H, J=5.8), 7.87 (dd, 1H,
J=8.3 and 2.5), 7.52–7.47 (m, 2H), 7.26 (dd, 1H, J=9.1 and 1.5),
4.54 (d, 2H, J=5.8), 2.57 (s, 3H), 2.30 (s, 3H).
MIC Determination against Mycobacteria
The measurement of the minimum inhibitory concentration
(MIC) against M. tuberculosis strains for each tested compound was
performed in 96-well flat-bottom, polystyrene microtiter plates in a
final volume of 100 ml. Ten two-fold drug dilutions in neat DMSO
starting at 50 mM were performed. Drug solutions were added to
Middlebrook 7H9 medium (Difco) and isoniazid (INH) (Sigma
Aldrich) was used as a positive control with two-fold dilutions of
INH starting at 160 mg/ml. The inoculum was standardized to
approximately 16107 cfu/ml and diluted 1 in 100 in Middlebrook
7H9 broth (Difco). This inoculum (100 ml) was added to the entire
plate but G-12 and H-12 wells were used as blank controls. All
plates were placed in a sealed box to prevent drying out of the
peripheral wells and incubated at 37uC without shaking for six
days. A resazurin solution was prepared by dissolving one tablet of
resazurin (Resazurin Tablets for Milk Testing; Ref 330884Y9
VWR International Ltd) in 30 ml of sterile PBS (phosphate
buffered saline). Of this solution, 25 ml were added to each well.
Fluorescence was measured (Spectramax M5 Molecular Devices,
Excitation 530 nm, Emission 590 nm) after 48 hours to determine
the MIC value.
M. bovis BCG strain Pasteur and derivatives were cultured
aerobically in Middlebrook 7H9 liquid medium (Difco) containing
0.05% (v/v) Tween-80, 10% (v/v) ADC and 0.25% (v/v) glycerol
at 180 rpm and 37uC. To cultivate the mycobacteria on solid
medium, Middlebrook 7H11 agar (Difco) with 10% (v/v) OADC
and 0.5% (v/v) glycerol was used. The MIC of the compounds on
solid media was evaluated by plating 104, 103, 102 and 101
bacteria on agar containing different concentrations of compound
in a dose response format. The MIC was defined as the lowest
concentration of compound resulting in the complete inhibition of
bacterial growth. Where applicable, liquid and solid media were
supplemented with 25 mg/ml Kanamycin. For all cloning proce-
dures, E. coli TOP 10 (Invitrogen) were used exclusively and
cultured in LB media containing 50 mg/ml Kanamycin at
180 rpm and 37uC.
General Antimicrobial Activity Assay
Whole-cell antimicrobial activity was determined by broth
microdilution using the Clinical and Laboratory Standards
Institute (CLSI) recommended procedure, Document M7-A7,
‘‘Methods for Dilution Susceptibility Tests for Bacteria that Grow
Aerobically’’. Some compounds have been evaluated against a
panel of Gram-positive and Gram-negative organisms, including
Enterococcus faecium, Enterococcus faecalis, Haemophilus influenzae,
Moraxella catarrhalis, Streptococcus pneumoniae, Escherichia coli and
Streptococcus pyogenes. The MIC was determined as the lowest
concentration of compound producing a .80% reduction in
growth as observed by OD.
HepG2 Cytotoxicity Assay
Actively growing HepG2 cells were removed from a T-175 TC
flask using 5 ml of Eagle’s MEM (containing 10% FBS/1%
NEAA/1% Penicillin+Streptomycin) and dispersed in the medium
by repeated pipetting. Seeding density was checked to ensure that
new monolayers were not more than 50% confluent at the time of
Table 1. Preliminary anti-tubercular activity, cytotoxicity and microsomal stability profile of the HTS hits identified in the IP series.
MIC (mM) Tox50 (mM) Mouse Human
IP H37Rvb Beijingb inh233b CDC1551b
M. bovis
BCG
Anti-
bacterial
panel Cell linesa
CLint
(ml/min/g
protein)
T1/2
(min)
CLint
(ml/min/g
protein) T1/2 (min)
1 0.2 0.03 0.03 0.06 1 all.64 all.25 .30 ,3 3.9 21
2 0.2 0.06 0.03 0.06 ND all.16 all.50 .30 ,3 .30 ,3
3 0.03 NDc ND ND 0.5 all.16 all.25 7 11.6 4.9 15.8
4 5 ND ND ND 5 all.16 all.50 7.4 11.4 2.3 .30
A small representative set of Gram-positive and Gram-negative organisms were analyzed in addition to the mycobacteria: Enterococcus faecium, Enterococcus faecalis,
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Escherichia coli and Streptococcus pyogenes.
aL1210, HepG2, NEURO 2A, MDCK and H9C2(2-1).
bM. tuberculosis strains.
cND, Not determined.
doi:10.1371/journal.pone.0052951.t001
Imidazo[1,2-A]Pyridines Active against TB
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52951
harvesting. The cell suspension was added to 500 ml of the same
medium at a final density of 1.26108 cells per ml. This cell
suspension (25 ml, typically 3000 cells per well) was dispensed into
the wells of 384-well clear bottom Greiner plates using a
Multidrop. Prior to addition of the cell suspension, plates were
dispensed with 250 nl of the screening compounds using an Echo
555. Plates were allowed to incubate at 37uC and at a relative
humidity of 80% for 48 hours in the presence of 5% CO2. After
the incubation period, the plates were allowed to equilibrate at
room temperature for 30 minutes before proceeding to develop the
luminescent signal. The signal developer, CellTiter-GloTM
(Promega) was equilibrated at room temperature for 30 minutes
and added to the plates (25 ml per well) using a Multidrop. The
plates were left for 10 minutes at room temperature for
stabilization and were subsequently read using a ViewLux (Perkin
Elmer).
Microsomal Fraction Stability Experimental Procedure
Pooled mouse, rat, dog and human liver microsomes were
purchased from Xenotech. Microsomes (final protein concentra-
tion 0.5 mg/ml, MgCl2 (final concentration 5 mM) and test
compound (final substrate concentration 0.5 mM; final DMSO
concentration 0.5%) in 0.1 M phosphate buffer pH 7.4 were pre-
incubated at 37uC prior to the addition of NADPH (final
concentration 1 mM) to initiate the reaction. The final incubation
volume was 600 ml. A control incubation was included for each
compound tested where 0.1 M phosphate buffer pH 7.4 was
added instead of NADPH (minus NADPH). One control
compound was included with each species. All incubations were
performed singularly for each test compound. Each compound
was incubated for 30 minutes and samples (90 ml) of incubate
were taken at 0, 5, 15, 20 and 30 minutes. The control (minus
NADPH) was sampled at 30 minutes only. The reactions were
stopped by the addition of sample to 200 ml of acetonitrile:-
methanol (3:1) containing an internal standard. The terminated
samples were centrifuged at 2,500 rpm for 20 minutes at 4uC to
precipitate the protein. Quantitative analysis: following protein
precipitation, the samples were analyzed using specific LC-MS/
MS conditions. Data analysis: from a plot of ln peak area ratio
(compound peak area/internal standard peak area) against time,
the gradient of the line was determined. Subsequently, half-life and
intrinsic clearance were calculated using the equations below:
Elimination rate constant (k) = (2 gradient).
Half life (t1/2) (min) =
0:693
k
Intrinsic Clearance (CLint) (ml/min/g protein) =
V|0:693
t1=2
where V= Incubation volume ml/g microsomal protein.
Pharmacokinetic Studies
For pharmacokinetic studies C57BL/6 female mice of 18–20 g
weight were used. Experimental compounds were administered
through oral gavage at 50 mg/kg dose at a concentration of
20 ml/kg. All mice received treatment in the fed state. Peripheral
total blood was the compartment chosen for the establishment of
compound concentrations. Drugs were administered as 1% methyl
cellulose suspensions and the blood sampling scheme was: 15, 30
and 45 minutes, 1, 1.5, 2, 3, 4, 8 and 24 hours. At each time-point,
blood from 4 different animals was obtained. LC-MS was used as
the analytical method of choice for the establishment of compound
concentration in blood with a sensitivity of LLQ=1–5 ng/ml in
25 ml blood. The non-compartmental data analysis was per-
formed with WinNonlin 5.0 and supplementary analysis was
performed with GraphPad 4 software. Dose-response studies in an
acute murine infection TB model were carried out as previously
described [28].
Generation of M. bovis BCG Spontaneous Mutants
Resistant to IP 1, 3 and 4
M. bovis BCG resistant mutants were generated by plating 108
mid-log (OD600 nm, 0.8–1.0) cells on solid media containing 56
MIC of each compound. Resistant colonies were subsequently
inoculated into liquid media in the absence of inhibitor. Putative
mutants were grown to mid-log and selected on solid media
containing 56MIC of the respective compound to confirm the
presence of a mutation conferring resistance to the inhibitor
relative to wild-type bacteria. Following the validation of the
mutants, the mutant and parental wild-type strains were inocu-
lated in parallel into 50 ml liquid media containing 26 (no
inhibitor for wild-type) the MIC of each compound, respectively.
Purified genomic DNA from each M. bovis BCG spontaneous
mutant and the M. bovis BCG wild-type (total of seven samples)
was prepared for sequencing using the Beckman SPRIworks
Fragment Library System I with adapters from the Illumina
Multiplexing Sample Preparation Oligonucleotide kit. DNA (3 mg)
was fragmented with a Bioruptor instrument (Diagenode, Lie,
Belgium) using 100 ml volume and 30 cycles. The fragments were
end-repaired, Illumina adapters were ligated and size selected
(300–600 bp) using SPRIworks. The size-selected fragments were
amplified (18 cycles using Phusion DNA Polymerase) and DNA
was purified with Agencourt AMPure XP beads (Beckman Coulter
Genomics, High Wycombe, UK). The median fragment size of the
final libraries was 420–575 bp (assessed by a BioAnalyzer High
Sensitivity LabChip, Agilent). Libraries were quantified with a
Quant-iT PicoGreen dsDNA kit (Life Technologies), diluted to
10 nM, pooled and sequenced at the University of Warwick on an
Illumina Genome Analyser IIx. Reads were aligned to the M. bovis
BCG Pasteur 1173P2 reference genome sequence (Genbank
accession number NC_008769.1) using the Burrows-Wheeler
Aligner (BWA) [29] version 0.5.9rc1 using the aln/sampe pipeline
with default settings, other than allowing for insert sizes up to 1000
bases in length. Putative variants were then detected using
samtools/bcftools 0.1.17. Aligned BAM files were supplied as
input to the samtools mpileup command using the command-line
modifiers ‘‘-C50 -D -S –E’’ and otherwise default settings [30].
Low-quality variants were initially filtered to exclude those with a
phred-scaled variant quality score of less than 60 and a strand bias
score (Fisher’s exact test) of greater than or equal to 0.005. The
putative effect of SNPs on coding sequences was determined using
snpEff 2.0.5d [31].
Recombinant DNA Manipulations
Standard molecular techniques were employed during the
cloning and DNA manipulations [32]. The production of all
oligonucleotide primers and the sequencing of generated con-
structs was performed by Eurofins MWG Operon; Ebersberg,
Germany. M. bovis BCG sequence data were obtained from
xBASE [33]. For the over-expression of M. bovis BCG QcrB in M.
bovis BCG, three strategies were adopted; qcrB, qcrCAB and the
entire ctaE-qcrCAB gene cluster including the predicted promoter
region were each cloned into the pMV261 vector (Kanamycin
resistance selection marker). The gene and gene clusters were
amplified by PCR (Phusion High-Fidelity DNA polymerase; New
England Biolabs) from M. bovis BCG strain Pasteur genomic DNA
using the oligonucleotide primers shown in Table 2. The resulting
Imidazo[1,2-A]Pyridines Active against TB
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fragments of sizes 1.7 kb, 3.8 and 4.6 kb were cloned into the
pMV261 vector by exploiting the BamHI and HindIII restriction
sites introduced via the primers (FastDigest restriction endonucle-
ases, Fermentas; T4 DNA ligase, New England Biolabs). All
constructs were verified by DNA sequencing. The three constructs
produced along with the empty pMV261 vector were electropo-
rated into M. bovis BCG as described previously [34].
Results
Identification of Imidazo[1,2-a]pyridines (IP) as Anti-TB
Agents and Optimization
As a result of the recently completed HTS campaign against M.
bovis BCG with hit confirmation in M. tuberculosis H37Rv, a
number of chemical families with potential anti-tubercular value
were recognized (results to be published elsewhere). Amongst those
families, we and others have identified imidazo[1,2-a]pyridines (IP)
as simple chemical scaffolds amenable to further lead optimization
(Figure 1) [10,23,24,25,26]. A preliminary profiling of the initial IP
1 and IP 2 (Table 1) showed how the compounds were potent and
selective anti-tuberculars with no evident signs of cytotoxicity.
Despite this interesting profile, the low stability observed in mouse
microsomal fractions precluded their progression to the available
in vivo acute murine TB efficacy model. Medicinal chemistry
efforts (details to be reported elsewhere) were hence dedicated to
the quick identification of an optimized compound that was able to
retain anti-tubercular potency while simultaneously improving the
metabolic degradation profile. These efforts led to the identifica-
tion of IP 3 and 4 (Figure 1, Table 1). The improved in vitro
metabolic stability found was then confirmed in a murine
pharmacokinetic model (Figure 2).
With these parameters in mind, lead compound IP 3 was then
progressed to a dose response efficacy study in an acute murine
model of TB infection (Figure 3). In this model, IP 3 was shown to
have bacteriostatic behavior in vivo, demonstrating a 2 log cfu
reduction with respect to a non-treated controls both at 300 and
500 mg/kg. No signs of toxicity were observed at any of the
administered doses.
Target Identification of the IP Chemical Family
The elucidation of the IP target is an important step towards the
validation of the inhibitor family as a suitable therapeutic anti-
tubercular agent. The three compounds IP 1, 3 and 4, exhibited
encouraging MIC values against M. tuberculosis (Table 1) and thus
were selected for use in strategies towards the identification of their
target. To establish M. bovis BCG as a suitable model for target
identification in this study, the MIC of the compounds were
determined as stated in Table 1. Using these values, M. bovis BCG
spontaneous resistant mutants were generated at 56MIC of each
compound. Resistant mutants derived against IP 1, 3, and 4 were
generated with a frequency of two, three and one respectively in
every 16108 cells. The resistant mutants contained one or more
mutations allowing them to survive in the presence of the
inhibitor, by either affecting drug accumulation within the cell
or by preventing the inhibitory impact of the drug on the target
itself. Identification of the mutation locus within the gene could
indicate the drug target. Whole-genome sequencing analysis
detected 16 putative high-quality single nucleotide polymorphisms
(SNPs) compared to the M. bovis BCG reference sequence, of
which five were likely to have arisen during laboratory storage of
the wild-type, parental strain and thus cannot be conferring the
phenotype. Three SNPs were predicted synonymous mutations,
Table 2. Primers used for the construction of pMV261::qcrB,
pMV261::qcrCAB and pMV261::ctaE-qcrCAB.
Primer Sequence (59R39)a
qcrB sense GATCGATCGGATCCAATGAGTCCGAAACTGAGTCC
qcrB anti-sense GATCGATCAAGCTTCTAGTGCTCGCCGTCTGG
qcrCAB sense GATCGATCGGATCCATTGACGAAACTGGGGTTCACC
qcrCAB anti-sense GATCGATCAAGCTTCTAGTGCTCGCCGTCTGG
ctaE-qcrCAB sense GATCGATCGGATCCTGATGGTCCCATGAGGATCAAC
ctaE-qcrCAB anti-sense GATCGATCAAGCTTGTGCTTGATTTGCCCGGTTC
aRestriction sites used for cloning are underlined (BamHI, HindIII).
doi:10.1371/journal.pone.0052951.t002
Figure 2. Whole blood pharmacokinetic profile and main
parameters of IP 3 after oral administration of a 50 mg/kg
suspension in 1% aqueous methylcellulose. Main pharmacoki-
netic parameters were established after non-compartmental analysis:
Cmax (maximum concentration observed in whole blood), 3.4 mg/ml;
AUC (Area Under the Curve) (0–8 hours), 4.36 mg.h/ml; F (percentage
bioavailability), 61%.
doi:10.1371/journal.pone.0052951.g002
Figure 3. Therapeutic efficacy of anti-tubercular IP 3 against M.
tuberculosis H37Rv in vivo. B6 mice were infected by intra-tracheal
instillation with 105 cfu M. tuberculosis H37Rv per mouse. The mice
were treated with the anti-tubercular orally once a day from day 1 to
day 8. Efficacy results are expressed as log cfu reduction in the lungs of
infected mice and are the mean6SD of five mice. The shaded line
indicates the levels of administered mycobacterial inoculum.
doi:10.1371/journal.pone.0052951.g003
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and two were for putative insertion/deletion events. Of the
remaining six putative non-synonymous SNPs, only one was
present in all six IP resistant mutants (Table 3). This SNP predicts
a single base change in qcrB (937ACC .937GCC) conferring a
predicted amino acid alteration (T313A) in the protein sequence.
According to TraSH analysis, qcrB is an essential gene [35,36,37].
Interestingly the mutant allele in this gene was present as a mixture
with the wild-type allele in the sequenced population. The
stochastic appearance of the other non-synonymous SNPs makes
it unlikely that they confer the phenotype and the gene in which
they occur can be assumed not the target of the IP family of
inhibitors. To confirm QcrB as the target of the three compounds
and to establish cross-resistance, the M. bovis BCG mutants
resistant to IP 1, 3 and 4 were plated at 56MIC of each of the
respective compounds (Figure 4). The results clearly demonstrate
that each M. bovis BCG resistant mutant raised against its
respective IP was viable in the presence of the other IP family
members. This result corroborates that QcrB is the target of the IP
family of inhibitors analyzed.
Over-expression of QcrB in M. bovis BCG
To further support the evidence that QcrB is the target of the IP
inhibitor family, QcrB was over-expressed in M. bovis BCG using
the expression plasmid pMV261 and the MIC of compound IP 3
was reassessed. This inhibitor was selected due to the low
quantities of drug required for full anti-tubercular activity
(Table 1). QcrB is a putative ubiquinol cytochrome c reductase
(subunit b), an integral member of the bc1 complex of the
respiratory electron transport chain. Following studies by Niebisch
and Bott [38], it has been reported that in the absence of a
functional QcrC, the expression levels of QcrB are severely
reduced, implying that QcrC is required in equimolar amounts for
the stable assembly of QcrB. As qcrB and qcrC are members of the
same operon, three cloning strategies were adopted to ensure the
over-expression of QcrB in a native conformation (Figure 5). The
first, qcrB alone was cloned into pMV261 (pMV261::qcrB). The
second, a fraction of the operon encompassing qcrC, qcrA and qcrB
(qcrCAB) was cloned (pMV261::qcrCAB), providing the probable
requirement of QcrC for the appropriate integration of QcrB into
the membrane. The third, the whole operon, including the
putative promoter region of ctaE, was cloned into pMV261 vector
(pMV261::ctaE-qcrCAB) to provide the natural promotors of all
enzymes, should the vector-encoded promotor region be insuffi-
cient to drive protein expression. All constructs were electropo-
rated into M. bovis BCG and the MIC of compound IP 3 was
assessed to examine the impact of the IP target over-expression
(Figure 6). In the absence of QcrB over-expression (pMV261
empty vector control), the MIC of IP 3 was unchanged with that of
wild-type M. bovis BCG. However, in conditions where the varying
constructs of qcrB were present in M. bovis BCG, the MIC of the
respective compound was increased from 0.5 mM to .8 mM
(Figure 6). These results further substantiate that QcrB is the target
of the IP drug series. Thus, QcrB over-expression has provided
supplementary inhibitor target, enabling the bacteria to survive at
drug concentrations that would normally be lethal.
Discussion
The IP compounds described here have been found to display
potent anti-tubercular activity against both M. bovis BCG and M.
tuberculosis. Furthermore the target of these inhibitors has been
identified as the b subunit of the cytochrome bc1 complex encoded
by the gene qcrB. The cytochrome bc1 complex or complex III of
the electron transport chain is an integral membrane protein that
forms a key component in the bacterial respiratory system. The
complex functions as a ubiquinol-cytochrome C reductase,
utilizing a catalytic core of three highly conserved components
namely the cytochrome c1, cytochrome b and the Rieske iron
sulfur protein [39]. A Q-cycle mechanism couples electron transfer
to proton translocation, adding to the proton electrochemical
gradient that is used to generate adenosine triphosphate (ATP).
The mechanism of electron transfer within the cytochrome bc1
complex has previously been described [40,41].
There are a number of well-characterized inhibitors of the bc1
complex. The elucidation of their mechanism and crystallographic
data identifying binding sites has lead to the development of
compounds that inhibit the function of the cytochrome bc1
complex for therapeutic purposes. These inhibitors tend to target
the two catalytic domains utilizing an analogous structure to either
quinone or quinol. von Jagow and colleagues [42] first character-
ized the most widely understood inhibitor of the cytochrome bc1
complex, myxothiazol, an antibiotic from Myxococcus fulvus.
Myxothiazol was found to inhibit the oxidant-induced reduction
of b cytochromes by competitively displacing quinone from the
Rieske iron sulfur protein at the high affinity binding site Qo with a
Kd ,1610
29 M [42]. Many other inhibitors have been identified
that function by the same mechanism as myxothiazol, such as
mucidin [43,44,45,46] and strobilurin A [44,47,48]. Another
inhibitor, antimycin [49], has been shown to inhibit the
cytochrome bc1 complex at a different location to myxothiazol,
Table 3. Single nucleotide polymorphisms detected in M. bovis BCG spontaneous mutants resistant to IP compounds.
M. bovis BCG
chromosomea
Codon
change
Amino acid
change Gene IP 1 IP 3 IP 4
mutant 1 mutant 2 mutant 1 mutant 2 mutant 3 mutant 1
225198 Gcc/Acc A103T fadD5 – – – A/T – –
663498 Tcc/Ccc S79P BCG_0584 – – – S/P – –
2439144 Acc/Gcc T313A qcrB T/A T/A A T/A T/A T/A
3100829 gCc/gTc A344V infB A/V A/V V – – –
3278815 Ctg/Gtg L351V lipN L/V L/V V – – –
3856853 gGc/gAc G294D BCG_3519 G/D G/D D – – –
Wild-type alleles are denoted by a ‘2’ character. Where mixtures of alleles were seen in the population this is indicated, e.g. A/V demonstrates both the genotype
coding for alanine and the genotype coding for valine is seen.
aGenomic positions are relative to M. bovis BCG str. Pasteur 1173P2 chromosome (Genbank accession: NC_008769.1).
doi:10.1371/journal.pone.0052951.t003
Imidazo[1,2-A]Pyridines Active against TB
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e52951
as it functions by binding to the Qi site, proximal to the BH heme,
inhibiting oxidation of the cytochrome b subunit [50].
Here we have reported QcrB as the target of the IP family of
compounds of the cytochrome bc1 complex, which was identified
by whole genome sequencing of resistant mutants. Resistant
mutants raised against all three compounds IP 1, IP 3 and IP 4
carried an SNP in the qcrB gene where a single base change
(937ACC .937GCC) translated to the substitution of a threonine at
position 313 for an alanine (T313A) in the cytochrome b subunit
(QcrB). In silico mapping of this amino acid substitution utilizing
the structure of a myxothiazol-bound cytochrome bc1 complex
[51] found the substitution did not fall within the myxothiazol
binding site, and therefore resistance is likely conferred by a
conformational change as opposed to a mechanistic alteration.
SNPs were also identified in other genes. However, due to their
inconsistent locations in the genomes of the IP resistant mutants
Figure 4. Cross-resistance of M. bovis BCG mutants resistant to IP compounds. M. bovis BCG resistant mutants raised against IP 1, 3 and 4
were plated at 56MIC of each of the respective compounds. A wild-type control demonstrates the resistant nature of the mutants.
doi:10.1371/journal.pone.0052951.g004
Figure 5. M. bovis BCG genome region harboring the genes for
the cytochrome bc1 complex and ctaE. The DNA regions cloned
into the pMV261 vector are indicated.
doi:10.1371/journal.pone.0052951.g005
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generated and their reported non-essentiality [35,36], these SNPs
were assumed to be non-consequential and not investigated
further.
In order to investigate the mechanistic similarities of the three
IP compounds in the series, cross-resistance of the genetically
dissimilar mutants was established. It was found that all mutants
generated were resistant to each of the IP compounds (Figure 4),
confirming T313A as the common factor in the resistant
phenotype and suggesting all three IP inhibitors function
identically. Despite the high potency of the inhibitors, there may
be a requirement for future re-engineering and lead optimization
now the QcrB target has been identified in this study. Neverthe-
less, the highly efficient bacterial clearance and novelty of the
target as a major component of the electron transport chain shows
considerable promise for IP compounds in the treatment of both
active and latent phase mycobacterial infection. The latter has
been shown to be particularly susceptible to inhibitors of the
electron transport chain [52].
Further evidence to support and validate our findings came
from the over-expression study of QcrB in M. bovis BCG using the
mycobacterial vector pMV261, which approximately exerts a 5
times copy number. Three varying length inserts were selected for
this study so as to ensure the synthesis of native QcrB, as depicted
in Figure 5. M. bovis BCG containing an empty pMV261 vector
exhibited no change in tolerance to IP 3 in comparison to the
wild-type strain, with an MIC of 0.5 mM. On the contrary, there
was a marked increase in MIC to .8 mM for M. bovis BCG
transformants containing all three inserts encompassing qcrB. At
166MIC, we found ample growth from all three inserts, including
pMV261::qcrB, despite the reported finding that QcrB was only
expressed to 10% efficiency if lacking functional QcrC in over-
expression vectors [38]. This result clearly confirms QcrB as the
target of IP 3 and the other IP compounds: increased expression
levels of the IP target enable higher concentrations of IP to enter
the cell and bind QcrB without a fatal impact on cell survival.
This study has revealed the IP inhibitor family as a promising
anti-tubercular agent, targeting an essential component of the
electron transport chain, QcrB. Due to the nature of the target, it
is conceivable that the IP compounds could target both active and
Figure 6. Effect on the MIC of IP 3 during the over-expression of QcrB in M. bovis BCG. The over-expression constructs pMV261,
pMV261::qcrB, pMV261::qcrCAB and pMV261::ctaE-qcrCAB were electroporated into M. bovis BCG and the MIC of IP 3 was evaluated. The plate lay-out
is shown (M. bovis BCG containing the construct detailed) and the MIC of IP 3 with reference to wild-type M. bovis BCG is stated along with the
corresponding concentration analyzed. Kanamycin was present at 25 mg/ml to select for the pMV261 vector.
doi:10.1371/journal.pone.0052951.g006
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latent phases of TB infection, an important requirement of future
anti-tubercular agents.
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